Under construction – not a live service
Sign in
Enrolling by invitationNo phase

Studies genetic changes in lung cancer that stops responding to targeted drugs

Studies tumor genes in lung cancer patients whose targeted drugs stopped working.

Key facts

Who runs it
Chang Gung Memorial Hospital
Where
Taoyuan, TaiwanSee the site
Trial code
Registry title
Integrated Genomics in Oncogene-driven NSCLC With Acquired Resistance
Status
Enrolling by invitation
People taking part
40 people, planned
Started
1 Sept 2025
Expected to end
11 May 2028
Type of study
Observational
Record updated
17 March 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with lung cancer (NSCLC) that has a known gene change and has grown again during treatment with a tyrosine kinase inhibitor (TKI).

Age
18 years or older
Sex
All sexes can join
Disease stage
Non-small cell lung cancer (NSCLC) confirmed under the microscope. The cancer has grown (progressive disease) during TKI treatment, as judged by the treating doctor.
Earlier treatment
Must have received a tyrosine kinase inhibitor (TKI) and had the disease progress on it.
Biomarker or test result
At least one known gene change before systemic treatment: EGFR exon 18-21 activating mutation, MET exon-14-skipping mutation, ERBB2 activating mutation, ALK fusion, ROS1 fusion, RET fusion, NTRK1 fusion, NTRK2 fusion, NTRK3 fusion, BRAF V600 mutation, or KRAS G12C mutation.

Main reasons for not taking part

  • Has not received a TKI
  • No documented disease progression during TKI treatment
  • No tumor tissue available for DNA extraction, or DNA quality too low for sequencing
  • Cannot give a blood sample for DNA sequencing

The registry criteria, word for word

Show all 6 criteriaShow less

Who can take part

  • Histologically confirmed NSCLC, with at least one of the known oncogene mutation prior to systemic treatment: EGFR exon 18-21 activating mutation, MET exon-14-skipping mutation, ERBB2 activating mutation, ALK fusion, ROS1 fusion, RET fusion, NTRK1 fusion, NTRK2 fusion, NTRK3 fusion, BRAF V600 mutation, or KRAS G12C mutation
  • Patient had received tyrosine kinase inhibitor (TKI) with progressive disease, as assessed by the treating physician
  • Had tumor tissue available for DNA extraction and sequencing
  • Eligible for withdrawal of a blood sample for DNA extraction and sequencing

Who cannot take part

  • Patient had not received TKI or did not have documented disease progression during TKI treatment
  • Tumor tissue was unavailable for DNA extraction or the DNA quality did not meet the sequencing requirement

Where in Taiwan

  • Chang Gung Memorial Hospital, Linkou BranchTaoyuan, TaiwanNo longer taking part

About the trial

What the trial wants to find out

Currently, tyrosine kinase inhibitor (TKI) remains the standard of care for oncogene-driven non-small cell lung cancer (NSCLC). However, almost all oncogene-driven NSCLCs would develop acquired resistance against TKI in clinical practice. Therefore, understanding the molecular mechanisms underlying the acquired resistance is a critical issue in lung cancer. Based on the literature, acquired resistance mechanism against EGFR TKI includes EGFR secondary mutation (T790M, C797X, L792X, G796X, L718Q, and exon 20 insertions), MET amplification, HER2 amplification, acquired gene fusions, and other complex alterations.

Read full original descriptionShow less

From the perspective of mutagenesis, the acquired resistance against TKI may be associated with APOBEC mutational processes, kataegis, chromothripsis, extrachromosomal DNA (ecDNA), and the interaction among them. However, still 30% to 50% of oncogene-driven NSCLCs had no identified mechanism attributed to the acquired resistance. Previous studies mostly used targeted-gene sequencing, which may overlook some structural variation and the transcriptomic dynamics. This study aims to investigate the genomic alterations, mutational processes, and the transcriptomic landscape underlying the acquired resistance using integrated genomics.

The group in the trial

  • Cohort 1

    Oncogene-driven NSCLC with acquired resistance to tyrosine kinase inhibitor

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Integrated Genomics in Oncogene-driven Non-small Cell Lung Cancer With Acquired Resistance to Tyrosine Kinase Inhibitors
Plain-language title
Studies genetic changes in lung cancer that stops responding to targeted drugsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
17 March 2026